Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA Young-A Heo Adis Drug Q&A Open access 05 February 2022 Pages: 57 - 63
Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use Esther S. KimSusan J. Keam Adis Drug Q&A 25 January 2022 Pages: 64 - 71
Several approved biologic agents are now available to treat paediatric plaque psoriasis Esther S. KimArnold Lee Practical Issues and Updates 17 February 2022 Pages: 72 - 76
Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication Mahesh Kumar BalasundaramAlok Singh Therapy in Practice 27 January 2022 Pages: 77 - 83
Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia Amjad AlfalehAbdullah AlkattanKhaled Alabdulkareem Original Research Article 22 January 2022 Pages: 84 - 92
Peak months of pandemic’s first-wave in India: a cross-sectional assessment of knowledge, attitudes and practice towards COVID-19 among internet-savvy individuals Jeevitha MarudachalamOviyha RavichandhiranHabeeb Ibrahim Abdul Razack Original Research Article 10 February 2022 Pages: 93 - 102
Correction to: Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA Young-A Heo Correction Open access 17 February 2022 Pages: 103 - 103
